Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average of $1.00

Atossa Therapeutics, Inc. (NASDAQ:ATOS)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.00 and traded as high as $1.51. Atossa Therapeutics shares last traded at $1.49, with a volume of 1,155,260 shares traded.

Analyst Upgrades and Downgrades

ATOS has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Atossa Therapeutics in a report on Tuesday, April 16th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 18th.

Atossa Therapeutics Trading Up 4.9 %

The stock’s 50-day moving average is $1.41 and its 200-day moving average is $1.00. The firm has a market capitalization of $186.70 million, a price-to-earnings ratio of -6.21 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Atossa Therapeutics, Inc. will post -0.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Atossa Therapeutics news, Director Jonathan Finn purchased 25,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The stock was purchased at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the transaction, the director now owns 25,000 shares in the company, valued at approximately $44,250. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Atossa Therapeutics

A hedge fund recently bought a new stake in Atossa Therapeutics stock. PFG Investments LLC purchased a new stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,650 shares of the company’s stock, valued at approximately $43,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.